Key facts
- · Type: New offering first sale 2026-01-08 · Amount sold: $25.99M · Total offering: $25.99M · SEC filing
- · Type: New offering first sale 2025-04-29 · Amount sold: $11.08M · Total offering: $11.08M · SEC filing
- · Type: New offering first sale 2024-03-26 · Amount sold: $15.07M · Total offering: $15.07M · SEC filing
- · Type: New offering first sale 2023-08-04 · Amount sold: $0 · Total offering: $10M · SEC filing
Is iBio, Inc. a real, registered company?
iBio, Inc. is a registered filer with the SEC (CIK 1420720) and has filed since 2023-08-15. 4 filings are on record, the latest on 2026-01-22.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
How much has iBio, Inc. raised?
Its new offerings report $52.14M sold across 3 offerings, as its own filings state.
Run the free check on iBio, Inc. →
SAN DIEGO, CALIFORNIA
Biotechnology
4
$52.14M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-01-22 | New offering first sale 2026-01-08 | $25.99M | $25.99M | SEC filing |
| 2025-05-07 | New offering first sale 2025-04-29 | $11.08M | $11.08M | SEC filing |
| 2024-04-04 | New offering first sale 2024-03-26 | $15.07M | $15.07M | SEC filing |
| 2023-08-15 | New offering first sale 2023-08-04 | $0 | $10M | SEC filing |
Keep reading
More on iBio, Inc. and the records around it.
iBio, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Aug 2026
- Form D filing Jan 2026
- Form D filing May 2025
- Who owns it
Companies that share a holder
- Patrick J. Crutcher also filed stake reports on 1 other company: Avalo Therapeutics, Inc. (Aug 2025)
- SilverArc Capital Management, LLC also filed stake reports on 8 other companies: Cellectar Biosciences Inc (Aug 2026), ELUTIA INC. (Aug 2026), TELA BIO, INC. (Aug 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), Stoke Therapeutics, Inc. (Aug 2026)
Watch iBio, Inc.
Get an email when iBio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with iBio, Inc.?
Who to contact
- Martin Brenner — Executive Officer, Director
- Felipe Duran — Executive Officer
- Evert Shimmelpennink — Director
- Alexandra Kropotova — Director
- William Clark — Director
- Gary Sender — Director
- David Arkowitz — Director
- Antonio Parada — Director
- Marc Banjak — Executive Officer
- Round: Form D filed 2026-01-22
- Amount sold: $25.99M
- Industry: Biotechnology
- Based: SAN DIEGO, CALIFORNIA
People listed
- Martin Brenner — Executive Officer, Director
- Felipe Duran — Executive Officer
- Evert Shimmelpennink — Director
- Alexandra Kropotova — Director
- William Clark — Director
- Gary Sender — Director
- David Arkowitz — Director
- Antonio Parada — Director
- Marc Banjak — Executive Officer
- Filing: Form D filed 2026-01-22
- Amount sold: $25.99M
- Industry group: Biotechnology
- Based: SAN DIEGO, CALIFORNIA
- Entity type: Corporation
We'll show it in your MentionFox inbox when iBio, Inc. raises, hires or launches. No email unless you switch it on.
Watch iBio, Inc. →Want the whole picture on iBio, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on iBio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on iBio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from iBio, Inc.'s own filings with the SEC. The people those filings name are on the team page.